Press Releases and News

July 12 2018

First Human Dosing of BT-11 Announced

Landos Biopharma Initiates Phase 1 Clinical Trial of BT-11, an Oral LANCL2 Agonist for Treatment of IBD BLACKSBURG, VA, July 12, 2018 – Landos Biopharma, Inc., a clinical-stage[...]

June 05 2018

New Data from Landos Biopharma

Landos Biopharma Announces Human Translational Results for Mechanisms of BT-11 in IBD at Digestive Disease Week 2018 BLACKSBURG, VA and WASHINGTON, DC June 5, 2018 – Landos[...]

May 18 2018

Landos Biopharma Recently Featured in BioCentury

BioCentury is the news service of record for the biotechnology and pharmaceutical industry, and they recently covered Landos’ lead asset for Crohn’s and ulcerative colitis, BT-11.[...]

September 20 2017

Landos featured in BioWorld

BioWorld Online is the news service of record for the biotechnology industry, and they recently prominently featured Landos’ $10M series A raise. To read the full article, please click here:[...]